KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers

Posted on May 27, 2015 by Evan C. Chen, Taylor A. Karl, Tomer Kalisky, Santosh K. Gupta, Catherine A. O’Brien, Teri A. Longacre, Matt van de Rijn, Stephen R. Quake, Michael F. Clarke, Michael E. Rothenberg

Receptor tyrosine kinase (RTK) inhibitors have advanced colon cancer treatment. We investigated the role of the RTK KIT in development of human colon cancer.

This entry was posted in News. Bookmark the permalink.